Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 21

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
ITEM 1.    FINANCIAL STATEMENTS 

Arrowhead Pharmaceuticals, Inc.

Consolidated Balance Sheets 

(in thousands, except per share amounts)

March 31, 2025September 30, 2024(unaudited)ASSETSCurrent assets:Cash, cash equivalents and restricted cash$185,709 $102,685 Accounts receivable2,365 — Available-for-sale securities, at fair value911,700 578,276 Prepaid expenses23,769 9,537 Other current assets11,677 4,973 Total current assets1,135,220 695,471 Property, plant and equipment, net384,803 386,032 Intangible assets, net7,711 8,562 Right-of-use assets44,452 45,255 Other assets1,312 4,482 Total Assets$1,573,498 $1,139,802 LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$9,980 $11,388 Accrued expenses78,450 63,017 Accrued payroll and benefits16,613 21,989 Lease liabilities6,782 6,342 Deferred revenue43,268 — Credit facility65,000 — Other liabilities448 432 Total current liabilities220,541 103,168 Long-term liabilities:Lease liabilities, net of current portion107,529 111,027 Liability related to the sale of future royalties352,276 341,361 Credit facility, net of current portion208,927 393,183 Total long-term liabilities668,732 845,571 Commitments and contingencies (Note 7)Noncontrolling interest and stockholders’ equity:Common stock, $0.001 par value:Authorized 290,000 shares; issued and outstanding 138,062 and 124,376 shares230 217 Additional paid-in capital2,106,864 1,806,000 Accumulated other comprehensive income4,390 4,750 Accumulated deficit(1,428,163)(1,625,523)Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity683,321 185,444 Noncontrolling interest904 5,619 Total noncontrolling interest and stockholders’ equity684,225 191